Cardio USMLE 9-26 (2) Flashcards
This patient presents with forgetfulness combined with intermittent right-sided abdominal pain, polyuria, and muscle weakness. In addition, his costovertebral angle tenderness and imaging point to the presence of kidney stones. These are the typical signs and symptoms of hypercalcemia (“Stones, bones, groans, and psychiatric overtones”). The most common causes of hypercalcemia are?
primary hyperparathyroidism and malignancy, which together account for over 90% of cases. While this is the “classic” presentation, in clinical practice, hypercalcemia is usually picked up on blood tests before symptoms develop.
Calcium stones are the most common type of kidney stones (80%–85%). Although most patients who develop calcium stones have normal levels of calcium in their blood, conditions that result in hypercalcemia, such as hyperparathyroidism, can also result in calcium stone formation. Cancers, such as squamous cell carcinoma of the lung, that produce PTH-related peptide as a paraneoplastic syndrome, or multiple myeloma induce?
calcium stone formation too.
The stones are made of calcium oxalate or calcium phosphate and are visible on both plain film and noncontrast CT scan. This differs from uric acid stones, which are radiolucent on plain film and opaque on CT scan. Other risk factors for kidney stone formation are excessive intake of vitamin D and milk-alkali syndrome.
Amitriptyline toxicity would promote urinary retention as well as confusion, constipation, and abdominal pain. Crohn disease can result in oxalate stone formation, where ileal involvement leads to fat malabsorption. Hyperuricemia would present with a combination of ?
psychiatric symptoms and kidney stones, but they would not be visible on plain film x-ray. Urinary tract staphylococcal infection with urease-positive microorganisms can result in large struvite calculi that are radiopaque.
Calcium stones are the most common type of renal stones; they appear radiopaque on plain film x-ray. Most patients with calcium stones will be normocalcemic, but some patients may have an underlying hypercalcemia, often secondary to ?
hyperparathyroidism or malignancy.
This patient presents with a testicular mass that he first noticed several months ago and begins chemotherapy. The development of shortness of breath, combined with a high FEV1/FVC ratio and increased interstitial fibrous tissue on lung biopsy, indicate that this patient has a restrictive lung disease. It is likely that this patient suffers from pulmonary fibrosis, a known complication of bleomycin, and was taking bleomycin for treatment of testicular cancer.
Bleomycin, which is active in?
G2 phase of the cell cycle, inhibits DNA synthesis through the generation of free radicals that bind DNA and cause strand breaks. It is used to treat testicular cancer and lymphoma. Toxicities of bleomycin include pulmonary fibrosis, minimal myelosuppression, and skin pigment changes.
Cisplatin and busulfan cross-link DNA during active and resting phases of the cell cycle but only busulfan causes lung toxicity. It’s not used to treat testicular cancer. Methotrexate inhibits dihydrofolate reductase in the S phase of the cell cycle. Etoposide is a chemotherapy agent that is not associated with?
lung toxicity. The most common lung toxicity with paclitaxel treatment is interstitial pneumonitis.
Bleomycin is a G2-phase–specific chemotherapeutic agent used to treat testicular cancer and lymphoma. It acts by?
inducing the formation of free radicals, which then cause DNA strand breaks.
The first step in salivation is secretion of saliva by acinar cells of the salivary glands. Saliva has approximately the same electrolyte composition as plasma. After it is secreted, it is then modified by ductal cells as it travels along the ducts. Impermeable to water, these ductal cells reabsorb sodium and chloride and secrete potassium and bicarbonate. Normally, the final composition of saliva is hypotonic to plasma because ductal cells tend to reabsorb more solute than they secrete. As secretory flow rate increases, the saliva spends less time exposed to the ductal cells, so the electrolyte composition remains similar to that of plasma. The only exception is bicarbonate, which is actually secreted at higher rates when the flow rate increases. This is because its secretion is selectively stimulated by?
parasympathetic activity when flow rate increases.
In this patient, who has an increased salivary flow rate, the salivary sodium and potassium content will remain similar to that in plasma, so sodium will be increased and potassium will be decreased relative to normal salivary electrolyte levels.
As the rate of salivation increases, less sodium is reabsorbed and less potassium is secreted. In this condition, salivary sodium will be?
increased while potassium will be decreased relative to normal salivary electrolyte levels.
This patient has a history of breast cancer and now returns with a new lump found on self-exam. Her previous breast cancer was found to be positive for HER-2 receptors, and trastuzumab, a monoclonal antibody against the HER-2 receptor, was successfully utilized to treat her disease. This patient is treated with trastuzumab again for the recurrence of breast cancer, but this time the drug is ineffective.
Chemotherapy failure (“ineffectiveness of treatment regimen”) results from tumor cell resistance to the effects of anticancer drugs, similar to the resistance that bacteria develop toward antibiotics. Resistance may be intrinsic and seen early in initial treatment, or acquired and become evident only when a treatment that was originally effective proves ineffective when used again in a subsequent regimen. There are several mechanisms by which tumor cells can acquire resistance. Because of their inherent genomic instability, cancer cells acquire many mutations over time. In this case, tumor cells survived initial therapy because of ?
mutations that altered the drug target. Imatinib (a tyrosine kinase inhibitor), all-trans retinoic acid, and the monoclonal antibodies are examples of other chemotherapeutic drugs that can become ineffective via this mechanism.
Although some cancer cells may decrease activation of anticancer drugs, this is not a mechanism that can be acquired. Acquired resistance is associated with?
an increase in Bcl-2 expression, not decreased tumor expression of Bcl-2. The effectiveness of trastuzumab would not be altered by increased sensitivity of the tumor to estrogen. A mutation in the p53 tumor suppressor gene is a form of primary (intrinsic) resistance, not acquired resistance.
Trastuzumab is a monoclonal antibody against the HER-2 receptor that is used to treat?
some breast cancers. Previously sensitive tumors can become resistant to this medication when a few remaining resistant tumor cells repopulate the tumor, similar to the process of antibiotic resistance in bacteria.
The patient is being treated for her triple-negative ductal breast cancer with a chemotherapeutic regimen including paclitaxel, which puts her at risk of drug-induced myelosuppression. The development of a persistent fever in this patient strongly indicates that she has an infection secondary to neutropenia. To address this, her physician added granulocyte colony-stimulating factor (G-CSF) to her existing drug regimen.
G-CSF receptor is present on the surface of granulocyte precursors in bone marrow, and its activation stimulates?
granulocyte (white blood cell) proliferation. CD34 is a marker found on pluripotent stem cells. CD34+ cells include those from the umbilical cord and bone marrow, endothelial progenitors of the blood vessels, mast cells, and certain dendritic cells. All CD34+ stem cells have the ability to differentiate in response to chemical and/or biologic stimuli. In the hematopoietic lineage, CD34+ stem cells can be stimulated to differentiate into erythroblasts and myeloblasts using G-CSF.
The B7 cell marker is expressed on antigen presenting cells and interacts with CD28 on T-helper cells.
CD28 is expressed on?
mature T-cells.
CD40 is a marker of macrophages.
CD56 is found on natural killer cells.
G-CSF is used to stimulate granulocyte production in patients with neutropenia, and acts by binding and activating pluripotent hematopoietic stem cells. Pluripotent hematopoietic stem cells are?
CD34+ and CD38-, and have the capacity to differentiate into erythroblasts and myeloblasts in response to biochemical stimuli.